Date Title
October 18, 2017
Realm Therapeutics - Block Listing Application
RNS Number : 8780T Realm Therapeutics PLC 18 October 2017     Realm Therapeutics plc ("Realm Therapeutics", "Realm" or the "Company")   Block Listing Application   18 October 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary
October 18, 2017
Realm Therapeutics - Holding(s) in Company
RNS Number : 8787T Realm Therapeutics PLC 18 October 2017   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of
October 17, 2017
Realm Therapeutics - Holding(s) in Company
RNS Number : 8774T Realm Therapeutics PLC 17 October 2017   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of
October 16, 2017
Realm Therapeutics - Holding(s) in Company
RNS Number : 7317T Realm Therapeutics PLC 16 October 2017   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of
October 16, 2017
Realm Therapeutics - Realm Therapeutics to speak at BIO Investor Forum
RNS Number : 6240T Realm Therapeutics PLC 16 October 2017       Realm Therapeutics plc ("Realm Therapeutics", "Realm" or the "Company")   Realm Therapeutics to Present at the 2017 BIO Investor Forum   Update on atopic dermatitis and allergic conjunctivitis clinical trials and recent financing   16
October 13, 2017
Realm Therapeutics - Holding(s) in Company
RNS Number : 5961T Realm Therapeutics PLC 13 October 2017   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of
October 13, 2017
Realm Therapeutics - Holding(s) in Company
RNS Number : 5957T Realm Therapeutics PLC 13 October 2017   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of
October 12, 2017
Realm Therapeutics - Holding(s) in Company
RNS Number : 4960T Realm Therapeutics PLC 12 October 2017   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of
October 12, 2017
Realm Therapeutics - Realm Therapeutics: Completion of £19.3m Placing
RNS Number : 4810T Realm Therapeutics PLC 12 October 2017     Realm Therapeutics plc ("Realm Therapeutics", "Realm" or the "Company")   Completion of £19.3 million ( $26 million ) Placing   Financing Brings New Healthcare Specialist Investors to Realm     12 October 2017 - Realm Therapeutics plc
October 12, 2017
Realm Therapeutics - Holding(s) in Company
RNS Number : 4480T Realm Therapeutics PLC 12 October 2017   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of
Displaying 71 - 80 of 156

Search Investor Relations